Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Summary
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of SHR-1314 Injection in Adults With Active Psoriatic Arthritis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2024-11-04
Completion Date
2026-06-30
Last Updated
2024-11-12
Healthy Volunteers
No
Conditions
Interventions
SHR-1314 injection
SHR-1314 injection
Placebo
Placebo
Locations (1)
Huashan Hospital of the Shanghai FuDan University
Shanghai, Shanghai Municipality, China